Found: 14
Select item for more details and to access through your institution.
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 3, p. 647, doi. 10.1007/s00432-021-03870-6
- By:
- Publication type:
- Article
Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
- Published in:
- Inflammatory Intestinal Diseases, 2018, v. 2, n. 3, p. 163, doi. 10.1159/000486131
- By:
- Publication type:
- Article
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2024, v. 210, n. 7, p. 919, doi. 10.1164/rccm.202311-2136OC
- By:
- Publication type:
- Article
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 2, p. 563, doi. 10.1007/s00262-020-02693-7
- By:
- Publication type:
- Article
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 12, p. 1825, doi. 10.1007/s00262-018-2239-4
- By:
- Publication type:
- Article
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 1, p. 39, doi. 10.1007/s00262-017-2061-4
- By:
- Publication type:
- Article
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
- Published in:
- Science Immunology, 2022, v. 7, n. 75, p. 1, doi. 10.1126/sciimmunol.abn9644
- By:
- Publication type:
- Article
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
- Published in:
- 2017
- By:
- Publication type:
- Letter
EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report.
- Published in:
- Case Reports in Oncology, 2013, v. 6, n. 2, p. 316, doi. 10.1159/000352086
- By:
- Publication type:
- Article
First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Outcome of mantle cell lymphoma patients treated at a single institution over the past decade.
- Published in:
- Hematological Oncology, 2014, v. 32, n. 4, p. 192, doi. 10.1002/hon.2123
- By:
- Publication type:
- Article
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 3, p. e210380, doi. 10.1001/jamanetworkopen.2021.0380
- By:
- Publication type:
- Article
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 5537, doi. 10.2147/CMAR.S179767
- By:
- Publication type:
- Article